Please provide your email address to receive an email when new articles are posted on . FRANKFURT, Germany — The ICL allows for reliable, predictable correction of low to high degrees of myopia with ...

Myopia, or nearsightedness, is at an all-time high among children in the US. Globally, half the population is expected to be nearsighted by 2050. Ophthalmologists are gravely concerned that these ...

A study conducted at Vanderbilt University Medical Center and 11 other hospitals and practices across the United States shows that use of low-dose atropine eyedrops, commonly used in a higher dose to ...

Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study. The global prevalence of myopia was estimated to be 30% to 34% in 2020 and ...

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, ...

Myopia affects roughly one third of the population worldwide ― a figure that is projected to reach 50% by 2050. Low-dose atropine, which helps curb the condition, currently is available in the United ...

Credit: Getty Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for NVK002 ...

Over 24 months, kids using the once-nightly drops and those using placebo saw mean changes in spherical equivalent refractive error (SER) of -0.82 D (95% CI -0.96 to ...

In the overall cohort of over 2,000 children in this retrospective observational study, the change in mean spherical equivalent from 2020 to 2021 was 2.2 times greater than the change from 2019 to ...